Cecile Le Brun

Dr. Cecile Le Brun

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in Emerging Infectious Diseases
Verified
Journal Article
Open access
CBCecile Le Brun
Cecile Le Brun
MGMartin Gombert
Martin Gombert
SRSylvie Robert
Sylvie Robert
EMEmmanuelle Mercier
Emmanuelle Mercier
PLPhilippe Lanotte
Philippe Lanotte

15 March 2022 in Pathogens
Verified
Journal Article
Open access
PDF file
EFEric Farfour
Eric Farfour
Laurent DORTETLaurent DORTET
Laurent DORTET
TGThomas Guillard
Thomas Guillard
NCNicolas Chatelain
Nicolas Chatelain
APAgathe Poisson
Agathe Poisson
OGon behalf of the GMC Study Group
on behalf of the GMC Study Group
In the context of increasing antimicrobial resistance in Enterobacterales, the management of these UTIs has become challenging. We retrospectively assess the prevalence of antimicrobial resistance in Enterobacterales isolates recovered from urinary tract samples in France, between 1 September 2017, to 31 August 2018. Twenty-six French clinical laboratories provided the susceptibility of 134,162 Enterobacterales isolates to 17 antimicrobials. The most frequent species were E. coli (72.0%), Klebsiella pneumoniae (9.7%), Proteus mirabilis (5.8%), and Enterobacter cloacae complex (2.9%). The overall rate of ESBL-producing Enterobacterales was 6.7%, and ranged from 1.0% in P. mirabilis to 19.5% in K. pneumoniae, and from 3.1% in outpatients to 13.6% in long-term care facilities. Overall, 4.1%, 9.3% and 10.5% of the isolates were resistant to cefoxitin, temocillin and pivmecillinam. Cotrimoxazole was the less active compound with 23.4% resistance. Conversely, 4.4%, 12.9%, and 14.3% of the strains were resistant to fosfomycin, nitrofurantoin, and ciprofloxacin. However, less than 1% of E. coli was resistant to fosfomycin and nitrofurantoin. We identified several trends in antibiotics resistances among Enterobacterales isolates recovered from the urinary tract samples in France. Carbapenem-sparing drugs, such as temocillin, mecillinam, fosfomycin, cefoxitin, and nitrofurantoin, remained highly active, including towards ESBL-E.

15 February 2022 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
ALAmélie Lombes
Amélie Lombes
RBRémy A. Bonnin
Rémy A. Bonnin
FLFrédéric Laurent
Frédéric Laurent
HGHélène Guet-Revillet
Hélène Guet-Revillet
EBEmmanuelle Bille
Emmanuelle Bille
Laurent DORTETLaurent DORTET
Laurent DORTET
In this multicentric study performed in 12 French hospitals, we reported that 26.9% (14/52) of the amoxicillin-clavulanate-resistant Proteus mirabilis isolates produced the OXA-23 carbapenemase. We found that an inhibition zone diameter of <11 mm around the amoxicillin-clavulanate disc was an accurate screening cutoff to detect these OXA-23 producers.

8 December 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
OBOlivier Bahuaud
Olivier Bahuaud
CBCecile Le Brun
Cecile Le Brun
ALAdrien LEMAIGNEN
Adrien LEMAIGNEN
Tularemia, caused by the bacterium Francisella tularensis, is an infrequent zoonotic infection, well known in immunocompetent (but poorly described in immunocompromised) patients. Although there is no clear literature data about the specific characteristics of this disease in immunocompromised patients, clinical reports seem to describe a different presentation of tularemia in these patients. Moreover, atypical clinical presentations added to the fastidiousness of pathogen identification seem to be responsible for a delayed diagnosis, leading to a” loss of chance” for immunocompromised patients. In this article, we first provide an overview of the host immune responses to Francisella infections and discuss how immunosuppressive therapies or diseases can lead to a higher susceptibility to tularemia. Then, we describe the particular clinical patterns of tularemia in immunocompromised patients from the literature. We also provide hints of an alternative diagnostic strategy regarding these patients. In conclusion, tularemia should be considered in immunocompromised patients presenting pulmonary symptoms or unexplained fever. Molecular techniques on pathological tissues might improve diagnosis with faster results.

8 March 2019 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
OBOlivier Bahuaud
Olivier Bahuaud
CBCecile Le Brun
Cecile Le Brun
TCThomas Chalopin
Thomas Chalopin
MLMarion Lacasse
Marion Lacasse
JMJulien Le Marec
Julien Le Marec
ALAdrien LEMAIGNEN
Adrien LEMAIGNEN
Tularemia is a rare zoonotic infection caused by bacterium Francisella tularensis. It has been well described in immunocompetent patients but poorly described in immunocompromised patients notably in solid organ transplant recipients. We report here two cases of tularemia in solid organ transplant recipients including first case after heart transplant. We also carried out an exhaustive review of literature describing characteristics of this infection in solid organ transplant recipients.

31 May 2024 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
PBPascale Bemer
Pascale Bemer
AAAlexandra Aubry
Alexandra Aubry
FSFrédéric Schramm
Frédéric Schramm
CKChristelle Koebel
Christelle Koebel
HRHélène Revillet
Hélène Revillet
OPOlivia Peuchant
Olivia Peuchant
Nontuberculous mycobacteria (NTM) bone and joint infections (BJIs) are uncommon. We evaluated the characteristics of BJIs and identified differences according to immune status. We performed a multicenter retrospective study in France involving patients with documented NTM BJI over a 9-year period. We collected the clinical and microbiological characteristics, management, and clinical outcomes of the patients. Overall, 95 patients were included, of whom 50.5% (48/95) were immunosuppressed. Tenosynovitis was more frequent in the immunocompetent group, and native arthritis more common in the immunosuppressed group. Mycobacerium marinum and M. abscessus complex were significantly more frequent in the immunocompetent group, and M. avium and M. xenopi were significantly more frequent in the immunosuppressed group. The combination of antibiotherapy with surgery tended to be more frequent in the immunocompetent than the immunosuppressed group (63.8% (30/47) vs 47.8% (22/46), respectively); of the latter, 45.7% (21/46) received antimicrobial therapy alone, a higher frequency than in the immunocompetent group (23.4%, 11/47). The median duration of antimicrobial treatment was similar in the two groups (11 months). Mortality was significantly higher in the immunosuppressed group. Although the clinical presentations and the NTM species involved in BJI differed according to immune status, most recovered completely after treatment.